Healthcare
Alterity Therapeutics Limited(PRNAF)
Live Price
Offline$0.055
+0.00% today
1Y Change
-63.33%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $110.00M
- Revenue Growth
- +35.3%
- EPS Growth
- +63.5%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Alterity Therapeutics Limited (PRNAF) is a Healthcare stock with a market cap of $110.00M and listed on OTC. The stock last traded around $0.06 and down 63.3% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +35.3%, EPS growth of +63.5%, a dividend yield of 0.0%. What stands out right now is revenue +35.3%, EPS +63.5%, free cash flow +9.2% with operating margin -525.6% and ROIC -31.3%. Valuation already assumes a fairly strong business story at price/sales 29.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PRNAF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+35.3% vs +7.6% peer median
Operating Margin
Below sector median
-525.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Feb 25, 2026 with an EPS surprise of -57.9% and a revenue surprise of -39.7%.
The operating story is still moving forward
Revenue is running at +35.3% and EPS at +63.5%, with operating margin around -525.6%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 28, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 25, 2026 | -57.9% | +0.0% | +0.0% | -98.0% |
2025 Aug 8, 2025 | +75.8% | +0.0% | +0.0% | +0.0% |
2025 Feb 28, 2025 | +20.8% | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRNAF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PRNAF Max Drawdown
-98.15%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PRNAF and SPY.
Company Overview
Alterity Therapeutics Limited
Other OTC
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
- Leadership
- David A. Stamler
- IPO Date
- Sep 25, 2012
- Employees
- 10
- Street Address
- 460 Bourke Street
- Mailing
- Melbourne, VIC, 3000
- Region
- Melbourne, VIC, AU
- Reporting Currency
- USD
- Investor Line
- 61 3 9349 4906
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 29.8
- Price/Book
- 2.0
Growth
- Revenue
- +35.3%
- EPS
- +63.5%
- Free Cash Flow
- +9.2%
Profitability
- Gross Margin
- 96.8%
- Operating Margin
- -525.6%
- Net Margin
- -380.7%
- ROE
- -30.2%
- ROIC
- -31.3%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 21.98
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.